INDIANAPOLIS – The U.S. Food and Drug Administration approved Eli Lilly’s Cymbalta (duloxetine HCl) for treatment of generalized anxiety disorder.
“Since generalized anxiety disorder can be a chronic illness, it is important that doctors and their patients find a treatment option that is effective in both the acute and maintenance phase of treatment,” said James M. Martinez, MD, U.S. Medical Director for Cymbalta, in a press release to PR Newswire. “With this additional approval, Cymbalta offers a new option for the maintenance treatment of this often-debilitating condition.” Cymbalta is made by Eli Lilly and Company (NYSE: LLY) of Indianapolis.
Other headlines in the field of health safety and recall include:
- Is there a history lesson from the swine flu of ’76? As more and more people receive the H1N1 shot, The Washington Post‘s David Brown looks at an earlier vaccine that is casting a public shadow over the attempt to immunize 200 million people in the next few months.
- Top iPhone apps for healthcare pros and their patients listed. Apps for the iPhone and iPod Touch can help healthcare pros provide better treatment, and help individuals lose weight, exercise and manage diabetes, Information Week reports. Apps include Epocrates, which keeps health data; SoundAMP, which turns an iPhone into a hearing aid; and Islet, a diabetic resource.